###begin article-title 0
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma
###end article-title 0
###begin p 1
The first two authors contributed equally to this publication.
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin title 3
Purpose
###end title 3
###begin p 4
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 166 173 <span type="species:ncbi:9606">patient</span>
To identify if recently described LOXL1 (lysyl oxidase-like 1) polymorphisms are associated with pseudoexfoliation glaucoma (XFG) in a United States (U.S.) Caucasian patient population.
###end p 4
###begin title 5
Methods
###end title 5
###begin p 6
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Individuals with XFG were identified using standard clinical examination techniques. TaqMan allelic discrimination assays were used to genotype 13 single nucleotide polymorphisms (SNPs) that tag LOXL1 in Caucasian individuals. The coding region of exon 1 that includes the previously associated SNP, , was sequenced. Allele and genotype frequencies were compared between cases and unrelated controls.
###end p 6
###begin title 7
Results
###end title 7
###begin p 8
###xml 340 345 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
Fifty affected individuals and 235 control individuals were recruited into this study. We replicated the previously reported association of three SNPs (, , and ) in our independent XFG population (single SNP p-values were 0.001-0.02). The risk alleles at these three and several other intragenic SNPs are part of an extended XFG-associated LOXL1 haplotype with a frequency of 32.0% in XFG patients and 21.6% in controls.
###end p 8
###begin title 9
Conclusions
###end title 9
###begin p 10
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 66 73 <span type="species:ncbi:9606">patient</span>
We have performed an analysis of LOXL1 and XFG in a United States patient population and have confirmed the strong association previously reported for Icelandic and Swedish samples. However, due to the high frequency of risk alleles in non-XFG individuals, this association should not form the basis of a diagnostic test for XFG. It is likely that additional genetic or environmental factors modulate the penetrance of LOXL1 susceptibility alleles.
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
Pseudoexfoliation syndrome (XFS) was initially described by Lindberg in 1917 [1] and further characterized by Vogt in 1925 [2]. It is a systemic disorder in which an unidentified, fibrillar substance is produced in abnormally high concentrations. The incidence of XFS varies among ethnic groups [3] with incidences of 20%-25% in the Scandinavian countries of Iceland and Finland [4] to 0% reported in Greenland Eskimos [5]. The Framingham Eye Study from the United States [6] revealed an overall incidence in non-glaucoma individuals of 0.6% at the age of 52-64 years that rose to 5.0% for 75-85-year-old individuals. Caucasians over 60 years old in the United States have an incidence of PEX around 1.6%-3% and African-Americans are approximately 0.4% [7,8].
###end p 12
###begin p 13
###xml 15 16 15 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 28 29 28 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
Both Lindberg [1] and Vogt [2] noted the association of XFS with glaucoma and increasing age, and it is a major cause of glaucoma throughout the world [3,9,10]. In general, the incidence of glaucoma in XFS patients in the United States appears to vary with the individual's ethnic background. The prevalence appears to be highest among individuals with Scandinavian ancestry and lower among African-Americans [8,11]. The reported prevalence of XFG varies among ethnic groups and ranges from 0.4%-28% of open angle glaucoma in the United States [8,11-13].
###end p 13
###begin p 14
###xml 31 33 31 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 204 209 204 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
Recently, Thorleifsson et al. [14] performed a genome-wide association study and identified a strong association of XFG with three single nucleotide polymorphisms (SNPs) in the lysyl oxidase-like 1 gene (LOXL1). They identified one intronic SNP () and two nonsynonymous coding SNPs ( and ) with significant disease association in Icelandic and Swedish individuals. This association was recently replicated in both the midwestern United States [15] and Australian [16] populations.
###end p 14
###begin p 15
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
LOXL1 belongs to the "LOX" family of extracellular enzymes that have multiple functions including the cross-linking of collagen and elastin by oxidatively deaminating lysine residues. Since XFS deposits are associated with the extracellular and basement membrane regions, the LOX genes are legitimate functional candidates to be involved with XFG pathogenesis [17]. There are five such enzymes (LOX, LOXL1, LOXL2, LOXL3, and LOXL4) that are involved with extracellular matrix metabolism. LOXL1 has been implicated in the pathogenesis of spontaneous cervical artery dissection [18] as well as bladder cancer [19].
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient ascertainment
###end title 17
###begin p 18
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
This study adhered to the tenets of the Declaration of Helsinki. The research protocol was approved by the Duke University Institutional Review Board, and all patients consented to participating in the study. All patients were examined by board certified glaucoma specialists.
###end p 18
###begin p 19
###xml 228 236 <span type="species:ncbi:9606">Patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
Pseudoexfoliation changes were identified as the presence of a central disk of XFS material, a clear annular zone (partial or complete), or flakes of XFS material on the lens surface, iris, or corneal endothelium in either eye. Patients were excluded if there was a history of exposure to intense infrared light, for example, glassblowing is associated with true exfoliation of the lens capsule rather than XFS. XFG was diagnosed when patients possessed the above XFS characteristics and at least two of the following criteria: A) documented intraocular pressure (IOP) >/=22 mmHg in either eye; B) glaucomatous optic nerve cupping defined as a cup to disc ratio >0.7 in either eye, notching of the neuroretinal rim, or an asymmetric cup to disc ratio >0.2; and/or C) glaucomatous visual field loss consistent with the optic nerve appearance. Glaucoma suspects were excluded from this study. All cases and controls were Caucasian. Controls were individuals of similar age as the patients without any evidence of pseudoexfoliation deposits on intraocular tissues. Their IOPs were in the normal range (<21 mmHg) with normal-appearing optic nerves.
###end p 19
###begin title 20
Single nucleotide polymorphism selection and genotyping methods
###end title 20
###begin p 21
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 479 484 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
Blood samples were obtained from each individual via peripheral venipuncture, and genomic DNA was isolated using standard techniques (Gentra, Minneapolis, MN). Tagging SNPs for Caucasian individuals were selected using Tagger in Haploview 3.32 with a pairwise r2 threshold of 0.8, based on genotype data generated by the . In addition to tagging SNPs, we also genotyped the three specific SNPs implicated by the previous study of XFG patients and controls [14]. See Figure 1 for LOXL1 gene structure and relative locations of SNPs used in this study. TaqMan allelic discrimination assays were performed for all SNPs per standard protocols from the manufacturer (Applied BioSystems, Foster City, CA). Two Centre d'Etude du Polymorphisme Humain (CEPH) standards were included in each 96-well plate for quality-control (QC), and samples from six individuals were duplicated across all plates with the laboratory technicians blinded to their identities. Genotype submission to the analysis database required matching QC genotypes within and across plates and at least 95% genotyping efficiency.
###end p 21
###begin p 22
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
LOXL1 gene structure with the position of each SNP as indicated
###end p 22
###begin p 23
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Diagrammatic representation of the LOXL1 gene. The relative positions of the 14 SNPs genotyped in this study are indicated below and demonstrate that both flanking and intragenic SNPs covering the entire gene were analyzed.
###end p 23
###begin title 24
Sequencing
###end title 24
###begin p 25
All sequencing was performed using appropriately selected primers and conditions optimized in a standard fashion. The coding region of exon 1 that included the SNP, , was sequenced because a TaqMan assay could not be designed. All sequencing was performed using an ABI 3730 capillary sequencer (Applied BioSystems).
###end p 25
###begin title 26
Statistical Analysis
###end title 26
###begin p 27
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
Genotype frequencies of XFG cases and controls were compared by logistic regression with adjustment for age and sex using SAS software (SAS Institute Inc., Cary, NC). Analysis of Hardy-Weinberg equilibrium (HWE) was performed separately for cases and controls using GDA software [20]. As in the original study by Thorleifsson et al. [14], SNP genotypes were coded according to a multiplicative (log-additive) model in which the disease risk in carriers of two variants is assumed to be the square of the risk in carriers of a single variant. Haplotype analysis was performed with the haplo.stats package [21,22].
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 525 526 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1455 1462 1453 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 1641 1646 1639 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 1847 1848 1845 1846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1857 1864 1855 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 1583 1591 <span type="species:ncbi:9606">patients</span>
Fifty XFG patients and 235 control individuals were recruited into this study. All patients (39 males-78% and 11 females-22%) and controls (145 males-61.7% and 90 females-38.3%) were Caucasian. The mean age of diagnosis was 74.0 (standard deviation,SD, was 8.0) years in patients; the age at recruitment was 64.9 (SD 11.6) years for the controls. All SNPs were in HWE in cases (p>0.05) and controls (p>0.05). Table 1 presents the results of the logistic regression analysis and the linkage disequilibrium (LD) coefficients (r2) between each genotyped SNP and the previously implicated XFG susceptibility marker,  (G153D). We confirmed the previously reported association between XFG and  (p=0.001),  (p=0.02), and  (p=0.02). Due to inter-marker LD, several other intragenic SNPs also showed evidence of association at p</=0.02. The haplotype analysis of SNPs,  and , confirmed that only three of the four possible haplotypes were observed in our sample (D'=1); the haplotype formed by the two protective alleles (T, A) was not detected. However, the frequency of the high-risk haplotype (G, G) in our population was lower than in the Icelandic and Swedish populations (United States: 69.9% in XFG cases, 46.6% in controls; Iceland: 81.4% in XFG cases, 49.8% in controls; and Sweden: 83.3% in XFG cases, 56.1% in controls). A haplotype analysis of all 12 SNPs with minor allele frequency (MAF)>5% confirmed that all individually associated SNPs (p<0.05 in Table 1) were part of the same XFG-associated haplotype, which had an estimated frequency of 21.6% in controls and 32.0% in XFG patients (haplotype-specific p-value was 0.03). All other LOXL1 haplotypes occurred at less than 10% frequency in controls. This is consistent with high pairwise D' values between the coding SNP, , and the other XFG-associated markers (D'>0.9) but relatively low r2 values (Table 1) due to different allele frequencies.
###end p 29
###begin title 30
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
Allelic association results for the 14 tagging single nucleotide polymorphisms in LOXL1
###end title 30
###begin p 31
###xml 104 108 104 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bold</bold>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
p values are based on a multiplicative model of risk. The three previously implicated SNPs are shown in bold [14]. Linkage disequilibrium coefficients (r2) of all genotyped SNPs with  are shown in the last column. OR stands for odds ratio, and CI stands for confidence interval.
###end p 31
###begin p 32
The two coding SNPs,  (R141L) and  (G153D), were analyzed for their ability to predict affection status. The  SNP demonstrated a 95.7% sensitivity (45 of 47 cases have the G allele) but only 13% specificity (28 of 215 controls lack the G allele) as a diagnostic test for XFG. The  SNP demonstrated a 100% sensitivity (49 of 49 cases have the G allele) but only 3.1% specificity (7 of 225 controls lack the G allele).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 21 23 21 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
Thorleifsson et al. [14] recently reported the results of a genome-wide association study of XFG that identified three strongly associated LOXL1 sequence variants, two of which were nonsynonymous coding SNPs. With this study, we have replicated these associations in a U.S. population of XFG patients and controls.
###end p 34
###begin p 35
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 544 549 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOXL1</italic>
However, we demonstrate that these associations are not strong enough to justify a diagnostic test for XFG. While the  and  SNPs individually have high sensitivity, their specificity is very poor (3.1% and 13.0%, respectively) due to their high prevalence in individuals without XFG. This same high prevalence of LOXL1 risk alleles has been reported in all populations examined to date: Nordic [14], midwestern United States [15], and Australian [16]. This suggests that additional genes or environmental factors affect the penetrance of these LOXL1 sequence variants. Further investigation of the complex etiology of XFG is warranted.
###end p 35
###begin title 36
Acknowledgments
###end title 36
###begin p 37
Grant support was from: NIH K23 EY014019, core grant EY01894, R01 EY015543, R01 EY13315, and a Research to Prevent Blindness (RPB) Sybil B. Harrington Scholar Award.
###end p 37
###begin title 38
References
###end title 38
###begin article-title 39
Lindberg and the discovery of exfoliation syndrome.
###end article-title 39
###begin article-title 40
Ein neues Spaltlampenbild des Pupillengebietes: Hellblauer Pupillensaumfilz mit Hautchenbildung auf der Linsenvorderkapsel.
###end article-title 40
###begin article-title 41
Exfoliation syndrome in various ethnic populations.
###end article-title 41
###begin article-title 42
Prevalence of pseudoexfoliation of the lens in Finns, Lapps, Icelanders, Eskimos, and Russians.
###end article-title 42
###begin article-title 43
Features of ocular pathology among the indigenous inhabitants of Chukotka.
###end article-title 43
###begin article-title 44
The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.
###end article-title 44
###begin article-title 45
The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study.
###end article-title 45
###begin article-title 46
Exfoliation syndrome. Prevalence in a southeastern United States population.
###end article-title 46
###begin article-title 47
Epidemiology of glaucoma in northern Europe.
###end article-title 47
###begin article-title 48
Exfoliation syndrome.
###end article-title 48
###begin article-title 49
Exfoliation syndrome prevalence in the glaucoma population of South Louisiana.
###end article-title 49
###begin article-title 50
Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma.
###end article-title 50
###begin article-title 51
Exfoliation syndrome.
###end article-title 51
###begin article-title 52
Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.
###end article-title 52
###begin article-title 53
###xml 60 68 <span type="species:ncbi:9606">Patients</span>
LOXL1 Mutations Are Associated with Exfoliation Syndrome in Patients from the Midwestern United States.
###end article-title 53
###begin article-title 54
Proteomic analysis of exfoliation deposits.
###end article-title 54
###begin article-title 55
Association between single nucleotide polymorphisms in the lysyl oxidase-like 1 gene and spontaneous cervical artery dissection.
###end article-title 55
###begin article-title 56
###xml 123 128 <span type="species:ncbi:9606">human</span>
LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.
###end article-title 56
###begin article-title 57
Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous.
###end article-title 57
###begin article-title 58
Score tests for association between traits and haplotypes when linkage phase is ambiguous.
###end article-title 58

